Gastrointestinal Cancer News

The FDA granted accelerated approval to dostarlimab-gxly for adults with mismatch repair-deficient recurrent or advanced solid tumors that progressed on or after prior treatment and who have no satisfactory alternative therapies.

The addition of sintilimab to first-line chemotherapy extended OS among patients with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma, according to topline results of a randomized phase 3 trial.

The FDA approved belzutifan for treatment of cancers associated with von Hippel-Lindau disease.

The FDA granted orphan drug designation to LP-184 for the treatment of pancreatic cancer.

In patients with colorectal neoplastic polyps, colon segments with complete resection compared with those after incomplete resection had a statistically significantly greater risk for future neoplasia and advanced neoplasia.

Detection rates for colorectal neoplasia were higher among computer-aided detection techniques vs. chromoendoscopy, according to research published in the Lancet Gastroenterology and Hepatology.

The fibrosis-4 index may be a useful screening method for hepatocellular carcinoma among patients with non-hepatitis B and non-hepatitis C virus, according to research published in BMC Gastroenterology.

In the treatment of locally advanced gastric cancer, apatinib combined with S-1 plus oxaliplatin was a safe and effective neoadjuvant treatment, according to a nonrandomized controlled study.

The FDA granted orphan drug designation to TST001 for treatment of gastric and gastroesophageal junction cancers, according to the agent’s manufacturer.

According to a study published in Therapeutic Advances in Gastroenterology, internal endoscopic drainage should be the first line endoscopic treatment of anastomotic fistulas when possible.